

Patent Docket P1101R2D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Camellia W. Adams et al.

Serial No.: 10/052798

Filed: November 2, 2001

For: APO-2 RECEPTOR

Group Art Unit: 1646

Examiner: to be assigned

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand delivered in an envelope addressed to: Assistant Commissioner of Patents, Washington,

_, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[] 37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date
of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR
§1.311, or an action that otherwise closes prosecution in the application, and is accompanied
by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR
§1.97(e), as checked below.

[] 37 CFR §1.97(d)

after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

Serial No.: 10/052798 Filed: November 2, 2001

Page 2

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patents or publications is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

- given for each listed item
- [] given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

Serial No.: 10/052798 Filed: November 2, 2001

Date: Howary 28, 2003

Page 3

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

RMaiseha

PATENT TRADEMARK OFFICE #121651



LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. P1101R2D1

Serial No. 10/052,798

Sheet 1

Applicant. Adams et al.

Filing Date

Group

02 Nov 2001

To Be Assigned

U.S. PATENT DOCUMENTS

Examiner	Γ	T	· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DOCUMENTS			
Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	08/799,861					13.02.97
	2	08/820,364		Gearing			12.03.97
	3	08/843,651		Holtzman			16.04.97
	4	08/843,652		Holtzman	Ì		16.04.97
	5	08/853,684		·			09.05.97
	6	08/869,852		,	•		04.06.97
	7	08/916,625					22.08.97
	8	09/042,583					17.03.98
	9	09/565,009					04.05.00
	10	09/712,726		Gearing		ļ	14.11.00
	11	2002/0048566	25.04.02	El-Deiry et al.		ļ	13.09.01
	12	2002/0048785	25.04.02	Holtzman			
	13	2002/0072091	13.06.02	Ni et al.			
	14	2002/0098550	25.07.02	Ni et al.		İ	
	15	2002/0160446	31.10.02	Holtzman		ł	
• •	16	4,855,235	08.08.89	Takahashi et al.			
	17	5,153,118	06.10.92	Wright, Jr. et al.			
	18	5,158,885	27.10.92	Bradstock et al.			
	19	5,763,223	09.06.98	Wiley et al.			
	20	6,313,269	06.11.01	Deen et al.	ł		
	21	6,455,262	24.09.02	Cox et al.	ľ		
•	22	60/040,846		•		1	17.03.97
	23	60/041,230					14.03.97
٠	24	60/054,021					29.07.97
	25	60/132,498					04.05.99
	26	60/133,238					07.05.99
	27	60/148,939]				13.08.99

FOREIGN PATENT DOCUMENTS

Examiner Initials	1	Document Number	Date	Country	Class	Subclass	Translation Yes No	
	28	WO 00/77191		PCT				
	29	WO 02/053727	11.07.02	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Chapman, "A Region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Chapman/FEBS Letters 374:216-220 (1995) 30

Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" Methods in Enzymology 288:15-27 (1997)

31

Examiner

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 2

		RIBBS			- C - IV-		
FORM PTO-1449			U.S. Dept. of Commerce	Atty Docket No.	Serial No.		
			Patent and Trademark Office	P1101R2D1	10/052,798		
			ratent and Trademan Cine	Applicant	•		
LIST	OF DIS	SCLOSURES CITED BY APPLICANT	Adams et al.				
(U	se sev	eral sheets if necessary)		Filing Date	Group		
•		· ·	02 Nov 2001	To Be Assigned			
		OTHER DISCLOS	SURES (Including Author, Title, Date,	Pertinent Pages, etc.)			
		Ellis, S., "Recognition of HLA-B2	7 and Related Antigen by a Mor	oclonal Antibody" <u>H</u>	uman Immunology		
	32	5:49-59 (1982)					
		Emery et al., "Osteoprotegerin Is	a Receptor for the Cytotoxic	Ligand Trail Journ	al of Interferon and		
	33	Cytokine Research (Abstract No. 2					
		Fishwild et al., "High-Avidity Hu	ıman IgGκ Monoclonal Antibodies	From a Novel Strai	n of Minilocus		
	34	Transgenic Mice" Nature Biotechno	ology. 14(7):845-851 (Jul 1996)				
		Glassy, M., "Production methods f	or generating human monoclona	antibodies" <u>Human</u>	Antibodies &		
	35	Hybridomas 4(4):154-165 (Oct 1993					
		Jones, Y., "Cytokine Receptor Com	nplexes Verses Cell Adhesion I	nteractions - Upping	the Affinity"		
	36	(Abstract no. M11.OA.002 presented at the XVIIIth IUCr Congress & General Assembly held in Glasgow,					
	<u> </u>	Scotland on August 4th-13th, 1999 Mendez et al., "Functional transp	olant of megabase human immuno	globulin loci recapi	tulates human antiboo		
	37	response in mice" Nature Genetics	5 15:146-156 (Feb 1997)	•			
		Olsson and Kaplan, "Human-human h	nybridomas producing monoclona	antibodies of pred	lefined antigenic		
	38	specificity" Proc. Natl. Acad. So	ci. USA 77(9):5429-5431 (1980)				
		Peterson, N., "Recombinant antibo	odies: alternative strategies	for developing and m	manipulating		
	39	murine-derived monoclonal antibod	dies" Laboratory Animal Science	<u>e</u> 46(1):8-14 (Feb. 1	1996)		
	ļ	Rabidezeh et al., "Induction of A	Apoptosis by the Low-Affinity	NGF Receptor" Science	ce 261:345-348 (1993)		
	40	Rabidezen et al., indaeten el-					
· ·	ļ	Steinitz et al., "EB virus-induce	ed B lymphocyte cell lines pro	ducing specific ant:	ibody" Nature		
	41	269(5627):420-422 (Sep 29, 1977)					
	 	Vaughan et al., "Human Antibodie:	s With Sub-nanomolar Affinitie	s Isolated From a La	arge Non-immunized		
	42	Phage Display Library" Nature Bio	otechnology 14:309-314 (1996)				
	-			<u>. </u>			
		-			•		
-	ļ						
	 						
		· · · · · · · · · · · · · · · · · · ·					
	 	<u> </u>					
	1						
·	↓						
	1		•				
	 						
	1		,				
	 			<u> </u>			
		·					
ļ <u></u>	1	-					
		<u> </u>		Date Considered			
Examin	er		•	Date Considered			
			1 100	D 600: drow line through	oitation		
*Exam	iner: I	nitial if reference considered, whether or no	ot citation is in conformance with MPE	r ous; araw line through n to applicant	Chanon		
if not	t in co	nformance and not considered. Include cop	by of this form with next communication	ii to applicant.			



In re Application of: Adams et al. Serial No.: 10/052,798 Filed On:Nov: 2, 2001

Hand Delivered On:

Docket No.: P1101R2D1 By: Diane L. Marschang Reg. No.: 35,600

The following has been received in the U.S. Patent Office on the date stamped:

Communication/Transmittal
Supplemental Information Disclosume Statement
Form 1449 with 42 References
Certificate of Hand Delivery

O3 WEGELVED ON 2900





Patent Docket P1101R2D1 =

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Camellia W. Adams et al.

Serial No.: 10/052798

Filed: November 2, 2001

For: APO-2 RECEPTOR

Group Art Unit: 1646

Examiner: To Be Assigned

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand delivered in an even choice addressed to: Assistant Commissioner of Patents, Washington, D

<u>3/3/</u> 2003 Leggie MtChill

TRANSMITTAL LETTER

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- 1. Supplemental Information Disclosure Statement;
- 2. Form PTO-1449 with 42 References;
- 3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Λ -

Diane L. Marschang

Reg. No. 35,600

Telephone No. (650) 225-5416

Date: Flbruary 28, 2003

09157

#129007

Revised (10/11/95)